Scientists have developed a new way to prevent breast cancer cells from spreading

Recently, in a study published in the International Journal of Oncogene, scientists from University of Manchester have developed a new method to effectively block the proliferation of breast cancer cells Research is expected to help develop new therapies for three negative breast cancer Because cancer does not respond to hormone therapy or targeted therapies for other forms of disease, the researchers plan to look for other treatments in this study; about 15% of breast cancer is triple negative breast cancer, which is easier to spread than general breast cancer, and patients often relapse after treatment; it is in young people, African Americans and Hispanics It is particularly common in women and in people with brac1 mutations Using the advanced CRISPR technology, researchers can effectively remove one of Runx2 and CBF β protein, and remove any one of them can block the spread of cancer, although the loss of CBF β seems to have a stronger effect, and after the removed protein is re expressed in cancer cells, cancer will continue to spread Researcher Paul Shore said that triple negative breast cancer is a very serious type of cancer, clinicians and scientists often spend a lot of time looking for new and better treatments; this study is an important milestone, which can help explain the mechanism of metastatic cancer spread, which is very important for the later development of effective treatment; however, looking for an intervention Describing the mechanism of the two protein functions may provide scientists with a target to help develop therapies for other cancers The researchers added that we must remember that these two proteins also exist in other healthy tissues, so the compounds used must find a way to avoid these healthy tissues or cells; kotryna Dr temsinaite said that the results of this study may help us understand the reason or mechanism of the difficulty in treating the spread of triple negative breast cancer in the body We hope to clarify the key role of CBF β protein in the spread of disease can help to develop new anti-cancer therapy At present, about 8000 people are diagnosed with triple negative breast cancer every year in the UK, which is very aggressive and easy to relapse, so many patients lack targeted therapy to treat this kind of cancer Later researchers will continue to conduct in-depth research to help fully clarify the key role of Runx2 and CBF β protein in cancer diffusion Meanwhile, relevant research also provides scientists with new targets, which is expected to help develop new targeted therapies for effective treatment of triple negative breast cancer Original source: